ERBB2 and gastric cancer: According to the newest National Comprehensive Cancer Network guidelines for advanced GC, nivolumab plus chemotherapy has been approved as the first‐line setting for patients with HER2‐negative advanced GC based on findings of CheckMate‐649 trial, particularly those with positive PD‐L1 expression (combined positive score [CPS] ≥5).9, 10